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Summary
This brief review summarizes current knowledge concerning
clinical characteristics of the hypoparathyroidism in DiGeorge
syndrome (DGS) and pathogenetic hypotheses based upon
studies in mouse models. Although a DiGeorge syndrome-like
phenotype may be etiologically heterogeneous, most cases are
caused by a genetic defect, i.e. an interstitial deletion of chro-
mosome 22 named e l 2 2 q 1 1. We focus on patients with this ge-
netic defect because a) within the population of patients with a
DGS-like phenotype, this is the predominant group of patients,
and b) both clinical and animal model studies have accumulat-
ed a wealth of information unavailable for, and mostly inapplic-
able to, patients with DGS-like phenotype without d el 2 2 q 1 1.
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Clinical features
Epidemiology
The most common underlying genetic defect, an interstitial,
heterozygous deletion of chromosome 22, band q11.2 (here re-
ferred to as del22q11) is relatively frequent, in one study, the
minimal incidence has been estimated at 1:7500 live births (1),
an incidence of 1:4000 has also been suggested (2). Not all
patients with del22q11 are diagnosed with hypocalcemia. In a
large survey of 340 patients with d e l 2 2 q 1 1, 203 (60%) had
been hypocalcemic, some of these (39%) had seizures (3) re-
sponsive to calcium supplements. Therefore, a simple calcula-
tion suggests that 1:12500 to 1:7000 live births is hypocalcemic
because of del22q11. These patients do not necessarily have a
fully fledged DiGeorge syndrome presentation, in fact, cases
have been reported where hypoparathyroidism is the promi-
nent clinical finding (4), although this is uncommon (5). 
Clinical presentation
This is a classic hypoparathyroidism that generally manifests it-
self in the neonatal period. The diagnosis is based upon labora-
tory analyses that show reduced calcium ion, hyperfos-
phatemia, low parathormone (PTH). Intravenous infusion of
PTH increases serum calcium as well as urinary and serum
cyclic AMP levels. Treatment is also that of classic hy-
poparathyroidism (e.g. calcium and active vitamin D). It is im-
portant, however, to recognize the underlying disease in these
patients because of the particular clinical history of the hy-
poparathyroidism in these patients (see below) but also be-
cause of other problems that d e l 2 2 q 1 1 patients often have and
that need to be recognized as early as possible (e.g. hearing
impairment, congenital heart disease, T-cell immune defects,
etc). Clinical descriptions of the DGS/VCFS/del22q11 syndrome
have been reviewed (2, 5-7). Briefly, there are three broad cate-
gories of clinical findings, “pharyngeal”, neurobehavioral, and
“others”. The pharyngeal group of clinical findings refers to
problems derived from developmental defects of the embryonic
pharyngeal apparatus: congenital heart disease (aortic arch ab-
normalities and or conotruncal defects) craniofacial anomalies,
external ear anomalies, velopharyngeal insufficiency, T-cell im-
mune defects (from hypoplasia or aplasia of the thymus),
hypocalcemia (from hypoplasia or aplasia of the parathyroids).
The neurobehavioral phenotype includes learning disabilities
and psychiatric disorders. The “others” category includes mis-
cellaneous findings like vascular anomalies, skeletal anomalies,
kidney anomalies, and other less common findings. 
As for most of the clinical findings associated with  e l 2 2 q1 1, hy-
poparathyroidism may or may not be present, and if it is present
may be of different clinical severity (8). Hypocalcemia may pre-
sent itself as the first dramatic clinical sign of the syndrome in
the neonate (9-12), and if the patient does not have congenital
heart disease (as it happens in 20-30% of d e l 2 2 q 1 1 patients) or
severe craniofacial abnormalities (which are not common), the
syndromic diagnosis may be very difficult at this age. At the oth-
er end of the spectrum, the patient may not have any hypocal-
cemic episode, but there may be a latent hypoparathyroidism,
i.e. revealed only by hypocalcemic challenge (13, 14). 
Clinical history
Generally, d e l 2 2 q 1 1 patients with hypoparathyroidism have
episodes of hypocalcemia in early life with resolution within the
first year of life. In one study, long term treatment was neces-
sary in 10 out of 40 patients (11). Stress or increased natural
requirement of calcium (e.g. during adolescence or pregnancy)
may trigger recurrence of hypocalcemic episodes or unmask
latent hypoparathyroidism (12, 15). Latent hypoparathyroidism
may be revealed in these patients by infusion of ethylendi-
aminotetracetic acid (16, 17). There are not enough data in the
literature to comment on how common latent or recurrence of
hypoparathyroidism is among del22q11 patients. 
Analysis of genetically engineered mouse models (described
below) provides a rationale for recurrence or latency of hy-
poparathyroidism. Indeed, the genetic defect causes a reduc-
tion of expression of the gene encoding PTH, most likely due to
the reduced number of cells expressing the gene. Therefore,
the capacity of PTH production is reduced, perhaps sufficient in
“normal” conditions, but may become insufficient if the demand
for PTH increases.
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DiGeorge syndrome derives from a developmental defect of
the pharyngeal apparatus. This is a transient embryonic sys-
tem, present only in vertebrates, composed tissue bulges (pha-
ryngeal arches) separated by epithelial invaginations (pharyn-
geal pouches) (6). The parathyroids and the thymus develop
from the endoderm of the third pharyngeal pouch. A number of
genes required for the formation or development of the third
pouch (e.g. Hoxa3, Pax1, Tbx1 and others) are also required
for the development of both parathyroids and thymus (review in
ref. 18). One of the first parathyroid-specific markers to appear
is the transcription factor Gcm2, shortly followed by the expres-
sion of PTH. G c m 2 mutation eliminates the parathyroids but
does not affect the thymus (19). Interestingly, the elimination of
the parathyroid glands is not sufficient to eliminate the produc-
tion of PTH as it can also be produced by thymic cells (19).
These considerations suggest that the hypoparathyroidism in
DiGeorge syndrome is more likely to derive from developmen-
tal problems of the pharyngeal pouches than from specific de-
fects of the parathyroids.
Genetics
The chromosomal deletion d el 2 2 q 1 1 eliminates a copy of over
30 genes, making it difficult to establish which gene (or genes)
is responsible for the hypoparathyroidism. Extensive genetic
manipulation of the mouse genome, however, has provided
substantial amount of information on this issue. The first mouse
model of d e l 2 2 q 1 1 was produced by deleting a mouse chromo-
somal segment homologous to that deleted in d e l2 2 q 1 1. Mice
carrying this deletion had heart defects similar to those found in
d e l 2 2 q 1 1 patients but did not have hypocalcemia or reduced
PTH serum levels (20). However, further analysis of these mice
demonstrated a strongly reduced level of expression of the PTH
gene in the developing parathyroids (21), providing evidence
that a gene within the mouse deleted region is a likely candidate
for the hypoparathyroidism in DiGeorge syndrome. Further ge-
netic analyses identified T bx 1, a gene included in the mouse
and human deletion, as a gene necessary for the formation of
thymus and parathyroids as well as other structures derived
from the pharyngeal apparatus (22, 23). T b x 1 h e t e r o z y g o u s
mutant mouse embryos have reduced expression of the P th
gene (Fig. 1A-B) just like mice with a chromosomal deletion
m deling d e l 2 2 q 1 1 (21). Hence, T b x 1 is a dosage sensitive
gene that when homozygously deleted prevents the formation
of the parathyroids, and when heterozygously deleted causes
reduced PTH gene expression and reduced parathyroid size.
The role of T b x 1 in human hypoparathyroidism has recently
been confirmed with the report of patients with T b x 1 m u t a t i o n s
associated with a DiGeorge syndrome phenotype, including hy-
poparathyroidism (24). Hence, T b x 1 haploinsufficiency is suffi-
cient to cause hypoparathyroidism in humans.
How Tbx1 functions in parathyroid development is still unclear.
It is clear, however, that Tbx1 mutation profoundly affects the
segmentation of the pharyngeal apparatus, eliminates the 3r d
and 4th pharyngeal pouches, and strongly reduces the number
of pharyngeal endodermal cells (23, 25). Hence, the most likely
scenario is that Tb x 1 affects parathyroids development be-
cause it affects the specification or proliferation of the endoder-
mal precursors of PTH-expressing cells, which also express
T b x 1. An indirect support for this model is the demonstration
that tissue-specific ablation of Tbx1 in the mesoderm does not
affect the formation of the third pharyngeal pouch (26) suggest-
ing a cell-autonomous function in endodermal cells. Further
analysis of T b x 1 function during parathyroid development is
necessary to confirm a cell-autonomous function in the endo-
dermal precursors of the parathyroids, and to test whether
Tbx1 has a role in this gland also after formation. Current mod-
els do not allow to test these hypotheses. 
Tbx1 may not be the only gene in the del22q11 important for
parathyroid development. Mouse mutants for the CRKLgene,
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Figure 1 - In situ hybridization of sagittal sections from mouse embryos at embryonic day 11.5 using a probe identifying the PTH gene transcript. The
hybridization signal is shown in red (arrows). A) Wild type (WT) embryo. B) Tbx1+/– embryo. Note the strong reduction of the hybridization signal,













another gene included in the d  l2 2 q 1 1 region, also have
thymic and parathyroid defects prospecting the interesting pos-
sibility that two genes may play a role in the human phenotype
(27). However, to date no mutations of this gene have been re-
ported in patients with DiGeorge syndrome phenotype.
Conclusions
Hypoparathyroidism in d el 2 2 q 1 1/DiGeorge syndrome may be
the earliest, and sometimes dramatic, clinical manifestation of
the disease. Although symptoms may disappear within the first
year of life, recurrence is possible. Conversely, d   2 2 q 1 1 p a-
tients may carry latent hypoparathyroidism that may be un-
masked later in life. Therefore, patients with del22q11 should
be monitored for parathyroid function throughout their lives.
The role of the T b x 1 as the causative gene for hypoparathy-
roidism is established, although contribution of other genes,
such as CRKL, cannot be ruled out. Mouse mutant model
analyses show a reduction of PTH-expressing tissue in het-
erozygous and complete absence of parathyroids in the ho-
mozygous mutants. This phenotype suggests a role of Tbx1 in
the specification and or expansion of endodermally-derived
precursors of endocrine parathyroid cells. 
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